Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for <font color="blue">advanced_3</font> <font color="blue">nasopharyngeal_3</font> <font color="blue">carcinoma_3</font> <font color="blue">:_3</font> positive effect on overall and progression - free survival . 
<br>
<br> <font color="blue">PURPOSE_1</font> <font color="blue">Nasopharyngeal_2</font> <font color="blue">carcinoma_2</font> <font color="blue">(_2</font> <font color="blue">NPC_2</font> <font color="blue">)_2</font> <font color="blue">is_2</font> <font color="blue">a_2</font> <font color="blue">radiosensitive_2</font> <font color="blue">and_2</font> <font color="blue">chemosensitive_2</font> <font color="blue">tumor_2</font> <font color="blue">._2</font> This randomized phase III trial compared concurrent chemoradiotherapy ( CCRT ) versus radiotherapy ( RT ) alone in <font color="blue">patients_4</font> <font color="blue">with_4</font> <font color="blue">advanced_4</font> <font color="blue">NPC_4</font> <font color="blue">._4</font> 
<br> <font color="blue">PATIENTS_1</font> <font color="blue">AND_1</font> <font color="blue">METHODS_1</font> <font color="blue">From_3</font> <font color="blue">December_4</font> <font color="blue">1993_4</font> <font color="blue">to_4</font> <font color="blue">April_4</font> <font color="blue">1999_4</font> <font color="blue">,_4</font> <font color="blue">284_7</font> <font color="blue">patients_7</font> <font color="blue">with_7</font> <font color="blue">1992_7</font> <font color="blue">American_7</font> <font color="blue">Joint_7</font> <font color="blue">Committee_7</font> <font color="blue">on_7</font> <font color="blue">Cancer_7</font> <font color="blue">stage_7</font> <font color="blue">III_7</font> <font color="blue">to_7</font> <font color="blue">IV_7</font> <font color="blue">(_6</font> <font color="blue">M0_6</font> <font color="blue">)_6</font> <font color="blue">NPC_6</font> <font color="blue">were_2</font> <font color="blue">randomly_2</font> <font color="blue">allocated_2</font> <font color="blue">into_1</font> <font color="blue">two_1</font> <font color="blue">arms_1</font> <font color="blue">._1</font> Similar dosage and fractionation of RT was administered in <font color="blue">both_1</font> <font color="blue">arms_1</font> <font color="blue">._1</font> The <font color="blue">investigational_1</font> <font color="blue">arm_1</font> received two cycles of concurrent chemotherapy with cisplatin 20 mg / m(2)/d plus fluorouracil 400 mg / m(2)/d by 96-hour continuous infusion during the weeks 1 and 5 of RT . Survival analysis was estimated by the Kaplan - Meier method and compared by the log - rank test . 
<br> <font color="blue">RESULTS_1</font> <font color="blue">Baseline_1</font> <font color="blue">patient_2</font> <font color="blue">characteristics_1</font> <font color="blue">were_1</font> <font color="blue">comparable_1</font> <font color="blue">in_1</font> <font color="blue">both_2</font> <font color="blue">arms_2</font> <font color="blue">._2</font> After a median follow - up of 65 months , 26.2% ( 37 of 141 ) and 46.2% ( 66 of 143 ) of <font color="blue">patients_1</font> developed tumor relapse in the <font color="blue">CCRT_1</font> <font color="blue">and_1</font> <font color="blue">RT_1</font> <font color="blue">-_1</font> <font color="blue">alone_1</font> <font color="blue">groups_1</font> <font color="blue">,_1</font> respectively . The 5-year overall survival rates were 72.3% for the <font color="blue">CCRT_1</font> <font color="blue">arm_1</font> and 54.2% for the <font color="blue">RT_1</font> <font color="blue">-_1</font> <font color="blue">only_1</font> <font color="blue">arm_1</font> ( P = .0022 ) . The 5-year progression - free survival rates were 71.6% for the CCRT group compared with 53.0% for the RT - only group ( P = .0012 ) . Although significantly more toxicity was noted in the <font color="blue">CCRT_1</font> <font color="blue">arm_1</font> <font color="blue">,_1</font> including leukopenia and emesis , compliance with the combined treatment was good . The second cycle of concurrent chemotherapy was refused by <font color="blue">nine_1</font> <font color="blue">patients_1</font> and was delayed for > or = 1 week for another <font color="blue">nine_1</font> <font color="blue">patients_1</font> <font color="blue">._1</font> There were no treatment - related deaths in <font color="blue">either_1</font> <font color="blue">arm_1</font> <font color="blue">._1</font> 
<br> <font color="blue">CONCLUSION_1</font> <font color="blue">We_1</font> <font color="blue">conclude_1</font> <font color="blue">that_1</font> <font color="blue">CCRT_1</font> <font color="blue">is_1</font> <font color="blue">superior_1</font> <font color="blue">to_1</font> <font color="blue">RT_1</font> <font color="blue">alone_1</font> <font color="blue">for_1</font> <font color="blue">patients_3</font> <font color="blue">with_3</font> <font color="blue">advanced_3</font> <font color="blue">NPC_3</font> <font color="blue">in_1</font> <font color="blue">endemic_1</font> <font color="blue">areas_1</font> <font color="blue">._1</font>